Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Agios Pharmaceuticals, Inc. (NASDAQ: AGIO ) began the morning with a strong move higher, and have continued to surge throughout the day -- as of this writing, shares were 34% higher than last night's close. The big pop is clearly the result of Agios' final earnings report of 2013, which showed a steeper-than-expected quarterly loss, but was otherwise was full of positive news.
So what: Agios' fourth-quarter revenue came in at $6.7 million, with $25.5 million reported for the full year, both of which bested analyst expectations for $6.2 million for the quarter and $25.1 million for the full year. A quarterly loss of $0.40 per share, while worse than the $0.34-per-share loss analysts had modeled, could be explained primarily by larger R&D expenses.
Agios is currently moving toward clinical trials for IDH1 mutant-inhibitor cancer treatment AG-120, which should begin anytime now, and is also pursuing two investigational new drug applications, including one for AG-348, an inborn errors-of-metabolism drug that should begin trials around midyear. The company will also present data from its phase 1 study of AG-221, an IDH2 mutant-inhibitor cancer drug at the American Association for Cancer Research meeting in April, which is sooner than expected and which appears to bode well for the quality of study results. These studies appear set to burn roughly $64 million of Agios' cash, as the company projects a year-end balance of roughly $130 million, as compared to 2013's year-end balance of $194 million.
Now what: Agios was largely flat since its IPO last until today's trade, because there really wasn't much information to go on for investors. While the company's updated the public somewhat on the progress of its drug candidates -- and the accelerated presentation timetable indicates some optimism for AG-221 -- there's really nothing much tangible to go on just yet.
Biotech isn't the only place for investors to find hyper-growth stocks
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.